Dementia among nursing home residents increased during COVID-19 lockdowns and non-profit institutions fared worse than for-profits, according to a report titled “Understanding Nonprofit and Government Ownership: Evidence from Nursing Homes in the Covid-19 Pandemic,” published by the Mercatus Center at George Mason University.

An influential organization is considering a revised definition of clinical death that could make it easier to declare a patient dead. A group within the Uniform Law Commission (ULC) that includes lawyers, medical...

Moderna and Pfizer plan to charge more than $130 for their COVID-19 shots, a big price jump from the government rate of $26.36.

"Given the drug only delays the onset of Diabetes Type 1 by two years, the drug’s wholesale price exceeds the cost of delayed conventional treatment by more than 10 times.” "“Drug companies charge high prices because they can.”

“I think the biggest factor has been cultural: cigarette smoking has become "uncool," largely due to an effective advertising campaign. Secondarily, a public education campaign has made most people concerned about the harmful health effects of smoking.”

“I really believe if we hadn’t been pouring all our time, money, and research dollars into the current unethical system, I think we would have found better solutions for people, such as augmenting the heart or providing an artificial one."

“The Health Equity Measures document is troubling because 'equity' is now a shapeshifting catch-all inviting politicization and racialization of healthcare."

The release fails to note that one of the two primary drugs used to treat COVID-19 patients in hospitals has been rheumatoid arthritis (RA) drug, Olumiant (baricitinib). WHO pushed for EUA in 2020. Olumiant, however, has a significant side effect: it can reduce resistance to fungal infection,

The rule would effectively roll back limitations on the application of the ACA provision put in place under the Trump administration. The 60-day public comment period ends on October 3.

“Price controls may be popular with those who benefit from artificially low prices but will ensure diabetic patients decades from now will not benefit from new advancements in technology because there will be no incentive to invest in newer insulins.”